HKU Scholars Hub: Browsing DSpace

Browsing by Author Hwang, SG

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 8 of 8

	Title	Author(s)	Issue Date	Views
	2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B Journal:Gastroenterology	Liaw, Y Gane, E Leung, N Zeuzem, S Wang, Y Lai, CL Heathcote, EJ Manns, M Bzowej, N Niu, J Han, S Hwang, SG Cakaloglu, Y Tong, MJ Papatheodoridis, G Chen, Y Brown, NA Albanis, E Galil, K Naoumov, NV	2009	201
	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection Journal:Gastroenterology	Yuen, MF Gane, EJ Kim, DJ Weilert, F Chan, HLY Lalezari, J Hwang, SG Nguyen, T Flores, O Hartman, G Liaw, S Lenz, O Kakuda, TN Talloen, W Schwabe, C Klumpp, K Brown, N	2019	35
	Evaluation of Estimated Glomerular Filtration Rate During Continuous 4-Year Treatment with Telbivudine in Patients with Bridging Fibrosis/Cirrhosis Proceeding/Conference:Journal of Hepatology	Gane, EJ Lai, CL Xie, Q Liaw, YF Thongsawat, S Chan, HLY Wang, Y Hwang, SG Safadi, R Jung, M Uddin, A Janssens, N Trylesinski, A	2014	41
	NVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg Proceeding/Conference:Journal of Hepatology	Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, JP Hwang, SG Nguyen, T Liaw, S Brown, N Klumpp, K Flores, O Hartman, G Gane, E	2016	130
	Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Hsu, CW Chen, YC Liaw, YF Gane, E Manns, M Zeuzem, S Wang, Y Lai, CL Hou, J Leung, N Bzowej, N Niu, J Jia, J Hwang, SG Cakaloglu, Y Ren, H Papatheodoridis, G Chen, Y Bao, W Lopez, P	2009	118
	Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients Proceeding/Conference:Hepatology International	Kennedy, W Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, J Hwang, SG Nguyen, T Westland, C Kakuda, T Brown, N Klumpp, K Flores, L Talloen, W Lenz, O Gane, E van Remoortere, P Chandra, S Fry, J	2017	81
	Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients Proceeding/Conference:Hepatology	DiBisceglie A, A Lai, CL Gane, E Chen, YC Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Zeuzem, S Rasenack, J Bzowej, N Han, SH Naoumov, N Hwang, SG Lim, SG Chao, GC Fielman, BA Brown, NA Study Group The GLOBE,	2006	138
	Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response Proceeding/Conference:Hepatology International	Lai, CL Gane, E Hsu, CW Chen, YC Thongsawat, S Wang, Y Chen, Y Naoumov, N Han, SH Hwang, SG Lim, SG Brown, NA	2007	154

Showing results 1 to 8 of 8